Document Detail

Acute and long-term effects of gallopamil (D 600) in stable angina pectoris--a randomized double-blind study
MedLine Citation:
PMID:  6421002     Owner:  NLM     Status:  MEDLINE    
The effects of the calcium-channel-blocking agent Gallopamil (D 600) were assessed in 20 patients with stable exertional angina pectoris in a randomized placebo-controlled double-blind protocol using serial exercise tests. Both after a single oral dose and during long-term treatment over 3 weeks, Gallopamil caused a dose-dependent increase in exercise duration and a reduction in ischemic ST segment depression that became clinically relevant using single doses of 50 mg. Since the rate-pressure product was not significantly affected by Gallopamil, its anti-anginal action cannot adequately be explained by a reduction in myocardial oxygen consumption as a result of this mechanism. The only side effects observed were asymptomatic second-degree sinoatrial block in one and first-degree atrioventricular block in another patient, each on 150 mg gallopamil daily. It thus seems justifiable to study the effectiveness of higher doses.
G Rettig; S Sen; H Schieffer; L Bette
Publication Detail:
Type:  Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Zeitschrift für Kardiologie     Volume:  72     ISSN:  0300-5860     ISO Abbreviation:  Z Kardiol     Publication Date:  1983 Dec 
Date Detail:
Created Date:  1984-03-12     Completed Date:  1984-03-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0360430     Medline TA:  Z Kardiol     Country:  GERMANY, WEST    
Other Details:
Languages:  ger     Pagination:  746-54     Citation Subset:  IM    
Vernacular Title:
Akut- und Langzeitwirkungen von Gallopamil (D 600) bei stabiler Angina pectoris--Eine randomisierte Doppelblindstudie.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angina Pectoris / drug therapy*
Clinical Trials as Topic
Double-Blind Method
Gallopamil / adverse effects,  therapeutic use*
Long-Term Care
Middle Aged
Random Allocation
Verapamil / therapeutic use*
Reg. No./Substance:
16662-47-8/Gallopamil; 52-53-9/Verapamil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Use of lasers for the excision of calcified heart valves--an experimental study
Next Document:  Lack of effect of nitroglycerin on the transmural variation of tissue pH during fixed coronary steno...